natgillin/translations-raw huggingface dataset:
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Pemetrexed Sandoz findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Pemetrexed Sandoz can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Plegridy findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Plegridy can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Portrazza findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Portrazza can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Praluent findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Praluent can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Praxbind findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Praxbind can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Pregabalin Accord findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Pregabalin Accord can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Pregabalin Mylan findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Pregabalin Mylan can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Pregabalin Mylan Pharma findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Pregabalin Mylan Pharma can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Pregabalin Sandoz findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Pregabalin Sandoz can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Pregabalin Sandoz GmbH findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Pregabalin Sandoz GmbH can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Pregabalin Zentiva findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Pregabalin Zentiva can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Quinsair findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Quinsair can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Raplixa findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Raplixa can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Rasagiline ratiopharm findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Rasagiline ratiopharm can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Ravicti findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Ravicti can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Raxone findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Raxone can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Rezolsta findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Rezolsta can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Ristempa findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Ristempa can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Rixubis findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Rixubis can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Saxenda findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Saxenda can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Scenesse findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Scenesse can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Senshio findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Senshio can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Simbrinza findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Simbrinza can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Sivextro findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Sivextro can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Spectrila findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Spectrila can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Strensiq findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Strensiq can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Sylvant findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Sylvant can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Synjardy findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Synjardy can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Tadalafil Mylan findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Tadalafil Mylan can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Tagrisso findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Tagrisso can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Taltz findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Taltz can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Tivicay findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Tivicay can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Translarna findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Translarna can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Trevicta findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Trevicta can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Triumeq findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Triumeq can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Trulicity findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Trulicity can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Ulunar Breezhaler findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Ulunar Breezhaler can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Unituxin findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Unituxin can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Vantobra findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Vantobra can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Vargatef findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Vargatef can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Vaxelis findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Vaxelis can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Velphoro findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Velphoro can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Viekirax findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Viekirax can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Vizamyl findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Vizamyl can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Vokanamet findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Vokanamet can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Voriconazole Hospira findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reportsslet den øverste linje.
The full EPAR and risk management plan summary for Voriconazole Hospira can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Vylaer Spiromax findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Vylaer Spiromax can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Wakix findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Wakix can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Xadago findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Xadago can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Xagrid findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR for Xagrid can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Xultophy findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Xultophy can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Xydalba findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Xydalba can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Zalviso findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Zalviso can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Zerbaxa findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Zerbaxa can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Zontivity findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Zontivity can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Zurampic findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Zurampic can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og risikostyringsplan for Entresto findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Entresto can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR om Dynepo findes her.
The full EPAR for Dynepo is available here.
Den fuldstændige EPAR om Emtriva findes her
The full EPAR for Emtriva can be found here.
Den fuldstændige EPAR om Nespo findes her.
The full EPAR for Nespo is available here.
Den fuldstændige EPAR om Omnitrope findes her.
The full EPAR for Omnitrope can be found here.
Den fuldstændige EPAR om Raptiva findes her.
The full EPAR for Raptiva can be found here.
Den fuldstændige EPAR om Stalevo findes på agenturets websted: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
The full EPAR for Stalevo can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Den fuldstændige EPAR om Targretin findes her.
The full EPAR for Targretin is available here.
Den fuldstændige europæiske offentlige vurderingsrapport for Bronchitol findes på agenturets websted under: : ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
The full EPAR for Bronchitol can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Den fuldstændige liste fremgår af indlægssedlen for ritonavir.
See the package leaflet provided with ritonavir for the full list.
Den fuldstændige liste over alle bivirkninger og begrænsninger ved Nivolumab BMS fremgår af indlægssedlen.
For the full list of all side effects and restrictions with Nivolumab BMS, see the package leaflet.
Den fuldstændige liste over alle bivirkninger ved Cyramza fremgår af indlægssedlen.
For the full list of all side effects with Cyramza, see the package leaflet.
Den fuldstændige liste over alle de indberettede bivirkninger for Mimpara fremgår af indlægssedlen.
For the full list of all side effects reported with Mimpara, see the Package Leaflet.
Den fuldstændige liste over alle de indberettede bivirkninger for Neulasta fremgår af indlægssedlen.
For the full list of all side effects reported with Neulasta, see the package leaflet.
Den fuldstændige liste over alle de indberettede bivirkninger ved Ablavar fremgår af indlægssedlen.
For the full list of all side effects reported with Ablavar, see the package leaflet.
Den fuldstændige liste over alle de indberettede bivirkninger ved Advate fremgår af indlægssedlen.
For the full list of all side effects reported with Advate, see the package leaflet.
Den fuldstændige liste over alle de indberettede bivirkninger ved Aflunov fremgår af indlægssedlen.
For the full list of all side effects reported with Aflunov, see the package leaflet.
Den fuldstændige liste over alle de indberettede bivirkninger ved Avaglim fremgår af indlægssedlen.
For the full list of all side effects reported with Avaglim, see the Package Leaflet.
Den fuldstændige liste over alle de indberettede bivirkninger ved Avonex fremgår af indlægssedlen.
For the full list of all side effects reported with Avonex, see the package leaflet.
Den fuldstændige liste over alle de indberettede bivirkninger ved Bretaris Genuair fremgår af indlægssedlen.
For the full list of all side effects reported with Bretaris Genuair, see the package leaflet.
Den fuldstændige liste over alle de indberettede bivirkninger ved Brinavess fremgår af indlægssedlen.
For the full list of all side effects reported with Brinavess, see the package leaflet.